7 completed, 2 terminated. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Terminated 1 |
Follow ARRY-371797: new trials by email Literature Review of ARRY-371797 trials Research Report on ARRY-371797
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation ARRY-371797 (PF-07265803), Placebo - Dilated Cardiomyopathy, Lamin A/C Gene Mutation | Phase 3 | Terminated | Pfizer | 77 | 2018-04-17 | 2024-01-09 |
| A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy ARRY-371797, p38 inhibitor, oral - LMNA-Related Dilated Cardiomyopathy | Phase 2 | Completed | Pfizer | 8 | 2015-02-02 | 2022-03-31 |
| A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy ARRY-371797, p38 inhibitor; oral - LMNA-Related Dilated Cardiomyopathy | Phase 2 | Completed | Pfizer | 12 | 2014-02-01 | 2020-10-14 |
| A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee ARRY-371797, p38 inhibitor; oral, Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral, Placebo; oral - Osteoarthritis of the Knee | Phase 2 | Completed | Pfizer | 157 | 2011-06-01 | 2020-10-14 |
| A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis ARRY-371797, p38 inhibitor; oral, Placebo; oral - Ankylosing Spondylitis | Phase 2 | Terminated | Pfizer | 25 | 2008-12-16 | 2020-10-19 |
| A Safety Study of ARRY-371797 in Healthy Subjects ARRY-371797, p38 inhibitor; oral, Placebo; oral - Healthy | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 40 | 2008-10-31 | 2022-05-05 |
| A Study of ARRY-371797 in Patients With Rheumatoid Arthritis ARRY-371797, p38 inhibitor; oral, Placebo; oral - Rheumatoid Arthritis | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 28 | 2008-07-01 | 2020-09-21 |
| A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction Placebo; oral, ARRY-371797, p38 inhibitor; oral, Celecoxib, COX-2 inhibitor; oral - Dental Pain | Phase 2 | Completed | Pfizer | 250 | 2008-04-07 | 2021-02-09 |
| A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction ARRY-371797, p38 inhibitor; oral, Placebo; oral - Dental Pain | Phase 2 | Completed | Pfizer | 103 | 2007-11-11 | 2021-02-21 |
Cardiomyopathy, Dilated (3) · Laminopathies (2) · Toothache (2) · Agnosia (1) · Arthritis, Rheumatoid (1) · Cardiomyopathies (1) · Heart Failure (1) · Limb-girdle muscular dystrophy, type 1B (1) · Osteoarthritis (1) · Osteoarthritis, Knee (1) · Pain (1) · Spondylitis, Ankylosing (1)
Pfizer (7) · Array Biopharma, now a wholly owned subsidiary of Pfizer (2)
United States (9) · Canada (2) · Argentina (1) · Belgium (1) · Italy (1) · Mexico (1) · Netherlands (1) · Norway (1) · Spain (1) · United Kingdom (1)
PMID 36718638, PMID 38979608, PMID 37010012, PMID 36114020, PMID 36515663, PMID 39145700, PMID 41693767
2017 (1)